Compounds for modulating chmp7
AssigneeIonis Pharmaceuticals, Inc.
InventorHuynh-Hoa Bui
Life of this patent
Estimating the term…
Abstract
Provided are compounds and pharmaceutical compositions for reducing the amount or activity of Charged Multivesicular Body Protein 7 (CHMP7) RNA in a cell or subject, and in certain instances reducing the amount of CHMP7 protein in a cell or subject. Such compounds and pharmaceutical compositions are useful to ameliorate diseases or conditions associated with aberrant activation of Endosomal Sorting Complexes Required for Transport-III proteins.
Claims74
An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to an equal length portion of a CHMP7 nucleic acid, and wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or 20 contiguous nucleobases of any of the nucleobases of SEQ ID NOs:
- 10-477, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 contiguous nucleobases complementary to:
- an equal length portion within nucleobases 3950-3983 of SEQ ID NO:
- 1;
- an equal length portion within nucleobases 4242-4266 of SEQ ID NO:
- 1;
- an equal length portion within nucleobases 4480-4525 of SEQ ID NO:
- 1;
- an equal length portion within nucleobases 4534-4566 of SEQ ID NO:
- 1;
- an equal length portion within nucleobases 5205-5232 of SEQ ID NO:
- 1;
- an equal length portion within nucleobases 5404-5430 of SEQ ID NO:
- 1;
- an equal length portion within nucleobases 8323-8344 of SEQ ID NO:
- 1;
- an equal length portion within nucleobases 16927-16950 of SEQ ID NO:
- 1;
- an equal length portion within nucleobases 17298-17340 of SEQ ID NO:
- 1;
- or
- an equal length portion within nucleobases 18287-18313 of SEQ ID NO:
- 1;
- wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, or at least 18 contiguous nucleobases of a sequence selected from:
- SEQ ID NOs:
- 220, 302, and 345;
- SEQ ID NOs:
- 21, 131, 191, and 465;
- SEQ ID NOs:
- 34, 116, 184, 242, 257, 340, and 474;
- SEQ ID NOs:
- 55, 118, 202, 267, 372, and 422;
- SEQ ID NOs:
- 73, 136, 197, and 421;
- SEQ ID NOs:
- 79, 160, 168, 230, 313, 331, and 464;
- SEQ ID NOs:
- 157, 186, and 265;
- SEQ ID NOs:
- 128, 182, and 309;
- SEQ ID NOs:
- 44, 76, 153, 206, 283, 363, and 416;
- or
- SEQ ID NOs:
- 85, 121, 189, 300, and 354;
- wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
Dependencies are inferred from the claim text.